对此，有业内人士分析认为，交易完成意味着该公司亏损光伏业务资产被剥离置出，此举将有助于改善 公司未来财务状况。 随着原控股股东的退出，新晋控股股东纵腾网络也引发市场关注。公开信息显示，纵腾网络成立于2009 年，以"全球跨境电商基础设施服务商"为企业定位，聚焦跨境仓储与物流，为全球跨境电商商户、出口 贸易企业、出海品牌商提供海外仓储、商业专线物流、定制化物流等一体化物流解决方案，旗下拥有谷 仓海外仓、云途物流、WORLDTECH等品牌。财务数据显示，2024年度，纵腾网络营业总收入271.05 亿元，净利润11.22亿元，公司总资产104.43亿元，总负债48亿元。 11月26日，《证券日报》记者致电*ST绿康拟进一步了解新控股股东等情况，公司工作人员回复称，以 公司公告披露为准。 由于公司2024年末经审计的归属于上市公司股东的净资产为负值、最近连续三个会计年度扣除非经常性 损益前后净利润均为负值，且2024年被出具"与持续经营相关的重大不确定性部分"的审计意见，根据 《深圳证券交易所股票上市规则》的规定，公司股票交易被实施"退市风险警示"及"其他风险警示"。 在此背景下，上市公司原控股股东方开始筹划控制权 ...

截至发稿，奥锐特市值为89亿元。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 王晓波） 每经AI快讯，奥锐特（SH 605116，收盘价：21.99元）11月21日晚间发布公告称，自2025年11月1日至 2025年11月21日，公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份约222万 股，占公司目前总股本的比例为0.55%，回购成交的最高价为22.59元/股，最低价为18.83元/股，支付的 资金总额为人民币约4623万元。 2025年1至6月份，奥锐特的营业收入构成为：自产原料药及中间体占比85.12%，制剂占比11.64%，贸 易占比2.74%，其他业务占比0.5%。 ...

每经AI快讯，天宇股份（SZ 300702，收盘价：23.69元）11月21日晚间发布公告称，浙江天宇药业股份 有限公司控股股东林洁女士持有公司股份约1.22亿股，占公司总股本的35.07%。截至目前，林洁女士累 计质押股份2000万股，占其持有公司股份总数的16.39%。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 曾健辉） 2025年1至6月份，天宇股份的营业收入构成为：仿制药原料药及中间体占比72.18%，CDMO原料药及 中间体占比16.02%，制剂占比11.43%，其他占比0.37%。 截至发稿，天宇股份市值为82亿元。 ...

2025年1至6月份，天宇股份的营业收入构成为：仿制药原料药及中间体占比72.18%，CDMO原料药及 中间体占比16.02%，制剂占比11.43%，其他占比0.37%。 截至发稿，天宇股份市值为92亿元。 每经AI快讯，天宇股份（SZ 300702，收盘价：26.5元）11月18日晚间发布公告称，公司第五届第十七 次董事会会议于2025年11月18日在公司一楼会议室以现场结合通讯表决的方式召开。会议审议了《关于 确认董事会审计委员会成员及召集人的议案》等文件。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 曾健辉） ...

Core Viewpoint - Zhongnong Lihua has announced the termination of its acquisition of a 50% stake in Taizhou Agricultural Materials Co., Ltd. due to the inability to reach final agreement on key terms with the shareholders involved [1][3]. Group 1: Acquisition Details - The acquisition was initially proposed on May 20, with the intention to purchase at least 50% of Taizhou Agricultural Materials from seven individual shareholders [1][3]. - The termination was mutually agreed upon after discussions and negotiations failed to yield consensus on core terms of the transaction [3]. Group 2: Company Performance - Zhongnong Lihua reported a revenue of 8.95 billion yuan for the first three quarters, reflecting a year-on-year increase of 5.11% [5]. - However, the net profit attributable to the parent company was 151 million yuan, showing a decline of 13.63% compared to the previous year [5]. - The company has indicated that the termination of the acquisition will not significantly impact its financial or operational status [3]. Group 3: Strategic Implications - The acquisition was expected to enhance Zhongnong Lihua's understanding of market demands and customer dynamics, thereby increasing market penetration in Zhejiang and surrounding areas [4]. - The termination of this deal means that the anticipated strategic benefits, such as improved product and service offerings, will not be realized [4]. - Despite this setback, Zhongnong Lihua plans to continue exploring potential cooperation opportunities with Taizhou Agricultural Materials [4].

【导读】中农立华终止收购台州农资不少于50%股份 中国基金报记者 李智 历时半年，中农立华的收购事项宣告终止。 中农立华终止收购台州农资50%股份 11月17日，中农立华发布公告称，公司与浙江省台州市农资股份有限公司（以下简称台州农资）的7位自然人股东陶维康、金果夫、刘海布、王伟民、胡 精良、黄伟胜、江志坚曾于5月20日签署《股份收购意向书》，拟以现金方式或其他方式收购上述自然人股东持有的台州农资不少于50%股份。 | 投资标的名称 | 浙江省台州市农资股份有限公司股份收购项目 | | --- | --- | | 投资金额(万元) | 元 | | 投资进展情况 | □完成 ☑终止 □交易要素变更 | | 特别风险提示(如有) | 公司前期与相关方所签署的《股份收购意向书》 旨在表达转受让双方对交易相关事宜的初步意 愿及初步商洽的意向性结果,属于意向性合作协 议。 | | | 因截至本公告日,转受让双方未能就投资交易达 成最终一致意见,拟终止本次对外投资,此事项 | | | 不会对公司财务状况和经营状况产生重大影响, | | | 不存在损害公司及股东利益的情形。 | 中农立华表示，《股份收购意向书》签署后，双方 ...

机构持仓方面，截止2025年9月30日，皓元医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股860.68万股，相比上期增加234.57万股。中欧医疗健康混合A（003095）位居第四大流通 股东，持股725.73万股，相比上期增加113.88万股。中欧医疗创新股票A（006228）位居第九大流通股 东，持股220.63万股，为新进股东。汇添富医药保健混合（470006）位居第十大流通股东，持股141.03 万股，为新进股东。 责任编辑：小浪快报 资料显示，上海皓元医药股份有限公司位于上海市浦东新区张衡路1999弄3号楼，成立日期2006年9月30 日，上市日期2021年6月8日，公司主营业务涉及小分子药物发现领域的分子砌块和工具化合物的研发, 以及小分子药物原料药、中间体的工艺开发和生产技术改进,为全球医药企业和科研机构提供从药物发 现到原料药和医药中间体的规模化生产的相关产品和技术服务。主营业务收入构成为：分子砌块、工具 化合物和生化试剂68.97%，其中:产品销售63.42%，原料药和中间体、制剂30.46%，其中:技术服务 5.55%，其他(补充)0.57%。 截至9月30日，皓元医药 ...

Core Viewpoint - Haoyuan Pharmaceutical's stock rose by 5.01% to 80.35 CNY per share, with a trading volume of 259 million CNY and a market capitalization of 17.042 billion CNY as of November 13 [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021 [1] - The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main revenue composition includes: molecular building blocks, tool compounds, and biochemical reagents (68.97%); product sales (63.42%); APIs and intermediates, formulations (30.46%); technical services (5.55%); and other (0.57%) [1] Fund Holdings - Hongta Hongtu Fund has a significant holding in Haoyuan Pharmaceutical, with its Hongta Hongtu Medical Selected Stock Fund A (020331) reducing its stake by 4,000 shares to hold 9,000 shares, representing 5.58% of the fund's net value [2] - The fund has achieved a year-to-date return of 33.15%, ranking 1506 out of 4216 in its category, and a one-year return of 18.94%, ranking 2064 out of 3951 [2] Fund Manager Information - The fund manager of Hongta Hongtu Medical Selected Stock Fund A is Cao Yang, who has been in the position for 2 years and 63 days [3] - The total asset size of the fund is 13.3331 million CNY, with the best return during his tenure being 30.03% and the worst being -33.52% [3]

每经AI快讯，亨迪药业（SZ 301211，收盘价：15.88元）11月11日晚间发布公告称，截至本公告日，刘 妍超累计质押股数约为1879万股，占其所持股份比例为7.06%。刘雯超累计质押股数约为1879万股，占 其所持股份比例为7.06%。刘思超累计质押股数约为1879万股，占其所持股份比例为7.06%。刘天超累 计质押股数约为1612万股，占其所持股份比例为6.06%。 2024年1至12月份，亨迪药业的营业收入构成为：原料药占比79.88%，制剂占比19.11%，其他占比 1.01%。 截至发稿，亨迪药业市值为66亿元。 每经头条（nbdtoutiao）——谁在替王家卫写《繁花》？揭秘影视剧本层层转包"枪手链" （记者 胡玲） ...

Company Overview - Zhejiang Zhenyuan's stock price increased by 2.04% on November 11, reaching 10.02 CNY per share, with a total market capitalization of 3.348 billion CNY [1] - The company has seen a year-to-date stock price increase of 27.64%, with a 5-day increase of 2.98%, a 20-day increase of 5.70%, and a 60-day increase of 5.70% [1] - Zhejiang Zhenyuan has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 21, where it recorded a net buy of -9.6038 million CNY [1] Business Performance - For the period from January to September 2025, Zhejiang Zhenyuan reported a revenue of 1.78 billion CNY, a year-on-year decrease of 37.59%, while the net profit attributable to shareholders was 56.0599 million CNY, reflecting a year-on-year increase of 28.67% [2] - The company's main business segments include retail (45.55%), wholesale (28.75%), industrial preparations (14.08%), raw materials (7.94%), health services (2.88%), and others (0.80%) [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.24% to 35,800, while the average circulating shares per person decreased by 14.70% to 7,877 shares [2] - The company has distributed a total of 228 million CNY in dividends since its A-share listing, with 60.1422 million CNY distributed in the last three years [3] Industry Context - Zhejiang Zhenyuan operates within the pharmaceutical and biological sector, specifically in pharmaceutical commerce and distribution, and is associated with concepts such as cold chain logistics, medical devices, and digital economy [2]